Media Articles Related to Invega (Paliperidone)
Study shows INVEGA SUSTENNA effective six months longer than common oral antipsychotics in treatment of schizophrenia
Source: Schizophrenia News From Medical News Today [2015.04.17]
A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA® (paliperidone palmitate) was effective six months longer than commonly prescribed oral...
New study found three-month paliperidone palmitate significantly delayed time to relapse in patients with schizophrenia
Source: Schizophrenia News From Medical News Today [2015.04.01]
Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to a new Phase 3...
Results announced from the QUALIFY study in schizophrenia
Source: Schizophrenia News From Medical News Today [2015.03.31]
Otsuka Pharmaceutical Europe Ltd. presented the results of the QUALIFY* study, which showed the superiority of Abilify Maintena compared to paliperidone palmitate when using the Heinrichs-Carpenter...
Discovery of communication link between brain areas implicated in schizophrenia
Source: Schizophrenia News From Medical News Today [2015.04.10]
Disruptions are in an inhibitory brain circuit between the thalamus and prefrontal cortexThe CSHL team induced PV interneurons of the medial prefrontal cortex (mPFC) to produce a red...
TSRI scientists find molecular trigger of schizophrenia-like behaviors and brain changes
Source: Autism News From Medical News Today [2015.04.09]
Scientists at The Scripps Research Institute (TSRI) have identified a molecule in the brain that triggers schizophrenia-like behaviors, brain changes and global gene expression in an animal model.
Published Studies Related to Invega (Paliperidone)
Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in
serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. 
CONCLUSIONS: These results suggest that paliperidone augmentation is well
An integrated approach for establishing dosing recommendations: paliperidone for
the treatment of adolescent schizophrenia. 
The Food and Drug Administration recently approved Invega for the treatment of
schizophrenia in adolescents 12 to 17 years. If dosing recommendations for this
population would have been based only on the results of the single efficacy trial
included in this program, paliperidone dosing in adolescents might have been
limited to 3 mg/d in adolescents less than 51 kg and to 6 mg/d in adolescents
greater than or equal to 51 kg...
Bilastine: in allergic rhinitis and urticaria. 
Bilastine is an orally administered, second-generation antihistamine used in the
symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and
urticaria. In two well designed phase III trials, 14 days' treatment with
bilastine was associated with a significantly lower area under the effect curve
(AUEC) for the reflective total symptom score (TSS) than placebo in patients with
symptomatic seasonal allergic rhinitis...
A randomized, placebo- and active-controlled study of paliperidone
extended-release as maintenance treatment in patients with bipolar I disorder
after an acute manic or mixed episode. 
patients with this disorder... CONCLUSIONS: Paliperidone ER significantly delayed the time to recurrence of any
Oral paliperidone: a review of its use in the management of schizoaffective disorder. [2011.06.01]
Oral paliperidone extended or prolonged release (Invega(R)) is an atypical antipsychotic, and is the first agent approved for the treatment of schizoaffective disorder. Paliperidone (or 9-hydroxyrisperidone) is the major active metabolite of the well known atypical antipsychotic risperidone, and its mechanism of action is thought to be the antagonism of dopamine D(2) and serotonin 5-HT(2A) receptors...
Clinical Trials Related to Invega (Paliperidone)
Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism [Not yet recruiting]
Our primary specific aim is to examine the efficacy of Paliperidone extended release
Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) compared to placebo in decreasing manic
symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. We
hypothesize that the Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) treated group will
have a statistically significant advantage on improvement in manic symptoms. They will also
have higher rate of treatment response and remission.
A Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia [Recruiting]
This study will explore the efficacy and safety of flexibly dosed paliperidone ER in
subjects with schizophrenia.
At the end of 12 months, flexible dose paliperidone treatment is expected to improve
functionality and satisfaction of schizophrenia patients significantly as measured by PSP.
The expected increase in PSP score is approximately 10-20%
Invega for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder [Recruiting]
This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the
treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or
Bipolar Spectrum Disorder. Specific hypotheses are as follows:
Hypothesis 1: Bipolar Disorder symptomatology in children and adolescents with DSM-IV
Bipolar I, Bipolar II, or Bipolar Spectrum Disorder will be responsive to Invega treatment.
Hypothesis 2: Invega - associated improvement in bipolar disorder symptomatology in children
and adolescents will translate into improved functional capacities (neuropsychological,
social, and occupational), as well as an increased quality of life throughout treatment.
Hypothesis 2: Invega treatment will be safe and well tolerated as reflected by a low drop
out rate and absence of major side effects.
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia [Recruiting]
Primary objective: To examine whether the switch to paliperidone ER from risperidone
improves cognitive function in stabilized patients with schizophrenia.
Secondary objectives: To compare the general clinical outcomes (efficacy and safety) after
switching to paliperidone ER from risperidone
A Study of Paliperidone Palmitate in Patients With Schizophrenia [Recruiting]
The primary objective of this study is to evaluate the efficacy of paliperidone palmitate as
compared with placebo in patients with schizophrenia. Secondary objectives of this study are
to evaluate the safety of paliperidone palmitate; to evaluate the improvement in global
symptoms as measured by the Clinical Global Impression - Severity (CGI-S) associated with
the use of paliperidone palmitate compared with placebo; and to explore the pharmacokinetics
of paliperidone palmitate through pharmacokinetic sampling.
Reports of Suspected Invega (Paliperidone) Side Effects
Extrapyramidal Disorder (31),
Drug Ineffective (30),
Weight Increased (27),
Abnormal Behaviour (22),
Tardive Dyskinesia (22), more >>